Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing

PLoS Pathogens

Volumn 7, Issue 6, 2011, Pages

  Bunnik, Evelien M ^a   Swenson, Luke C ^b   Edo Matas, Diana ^a,d   Huang, Wei ^c   Dong, Winnie ^b   Frantzell, Arne ^c   Petropoulos, Christos J ^c   Coakley, Eoin ^c   Schuitemaker, Hanneke ^a,d   Harrigan, P Richard ^b   van 't Wout, Angélique B ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c MONOGRAM BIOSCIENCES   (United States)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ANTIGEN DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MOLECULAR PHYLOGENY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PYROSEQUENCING; VIRUS ENVELOPE; VIRUS LOAD; VIRUS MUTATION; EVOLUTION; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SEQUENCE ANALYSIS; TIME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOLOGICAL EVOLUTION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; TIME FACTORS;

EID: 79959848815     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002106     Document Type: Article

References (55)

1. Zhu T, Mo H, Wang N, Nam DS, Cao Y, et al. (1993) Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261: 1179-1181.
2. Van 't Wout AB, Kootstra NA, Mulder-Kampinga GA, brecht-van LN, Scherpbier HJ, et al. (1994) Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 94: 2060-2067.
3. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7557.
4. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289.
5. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, De Goede REY, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 66: 1354-1360.
6. Koot M, Keet IPM, Vos AHV, De Goede REY, Roos MThL, et al. (1993) Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681-688.
7. Richman DD, Bozzette SA, (1994) The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169: 968-974.
8. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR, (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628.
9. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, et al. (2007) Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 81: 7885-7893.
10. Koot M, Van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, et al. (1996) Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 173: 349-354.
11. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66: 1354-1360.
12. O'Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, et al. (1990) HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348: 69-73.
13. Chesebro B, Nishio J, Perryman S, Cann A, O'Brien W, et al. (1991) Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 65: 5782-5789.
14. Shioda T, Levy JA, Cheng-Mayer C, (1992) Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89: 9434-9438.
15. Groenink M, Fouchier RAM, Broersen S, Baker CH, Koot M, et al. (1993) Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260: 1513-1516.
16. Fouchier RAM, Broersen SM, Brouwer M, Tersmette M, Van 't Wout AB, et al. (1995) Temporal relationship between elongation of the HIV-1 gp120 V2 domain and the conversion towards a syncytium inducing phenotype. AIDS Res Hum Retroviruses 11: 1473-1478.
17. Pastore C, Ramos A, Mosier DE, (2004) Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 78: 7565-7574.
18. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, et al. (2006) Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 80: 750-758.
19. Carrillo A, Ratner L, (1996) Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 70: 1301-1309.
20. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, et al. (2008) Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 82: 5584-5593.
21. Fouchier RAM, Groenink M, Kootstra NA, Tersmette M, Huisman HG, et al. (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183-3187.
22. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J, (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777-6780.
23. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA, (1993) A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 67: 3649-3652.
24. Harrowe G, Cheng-Mayer C, (1995) Amino acid changes in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1. Virology 210: 490-494.
25. Kuiken CL, De Jong J-J, Baan E, Keulen W, Tersmette M, et al. (1992) Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 66: 4622-4627.
26. Van 't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C, et al. (1998) Evolution of syncytium inducing and non-syncytium inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection. J Virol 72: 5099-5107.
27. Koot M, Vos AHV, Keet RPM, De Goede REY, Dercksen W, et al. (1992) HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 6: 49-54.
28. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, et al. (1993) Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 37: 1095-1101.
29. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, et al. (2007) Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51: 566-575.
30. Reeves JD, Coakley E, Petropolous CJ, Whitcomb JM, (2009) An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 3: 94-102.
31. Chesebro B, Wehrly K, Nishio J, Perryman S, (1996) Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 70: 9055-9059.
32. Hung CS, Vander HN, Ratner L, (1999) Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 73: 8216-8226.
33. Jensen MA, Li FS, Van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
34. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, et al. (2007) Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21: F17-F24.
35. Coakley E, Reeves JD, Huang W, Mangas-Ruiz M, Maurer I, et al. (2009) Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother 53: 4686-4693.
36. Verhofstede C, Vandekerckhove L, Eygen VV, Demecheleer E, Vandenbroucke I, et al. (2009) CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J Acquir Immune Defic Syndr 50: 126-136.
37. Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, et al. (2010) Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405: 492-504.
38. Graham RL, Hell P, (1985) On the History of the Minimum Spanning Tree Problem. IEEE Ann Hist Comp 7: 43-57.
39. Vauterin L, Vauterin P, (2006) Integrated databasing and Analysis. In: Stackebrandt E, editors. Molecular identification, systematics, and population structure of prokaryotes Heidelberg Springer pp. 141-218.
40. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
41. Regoes RR, Bonhoeffer S, (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13: 269-277.
42. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
43. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, et al. (2008) Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359: 1442-1455.
44. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, et al. (2009) Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 200: 1724-1728.
45. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 4: e5683.
46. Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, et al. (2011) Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 25: 611-617.
47. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
48. Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, et al. (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 49: 4911-4919.
49. Archer J, Braverman MS, Taillon BE, Desany B, James I, et al. (2009) Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23: 1209-1218.
50. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, et al. (2010) Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and "Deep" Sequencing to Plasma RNA and Proviral DNA. J Acquir Immune Defic Syndr 54: 506-510.
51. Bushman FD, Hoffmann C, Ronen K, Malani N, Minkah N, et al. (2008) Massively parallel pyrosequencing in HIV research. AIDS 22: 1411-1415.
52. Hall TA, (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
53. Swofford DL, (2002) PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods), version 4 [computer program] Sunderland, Massachusetts Sinauer Associates.
54. Saitou N, Nei M, (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
55. Hasegawa M, Kishino H, Yano T, (1985) Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol 22: 160-174.